In addition, efforts have been made to design PROTACs and molecular glues that can degrade BET proteins by utilizing the intracellular ubiquitin proteasome system.1343 A clinical trial is currently underway for the FHD-609 degrader in the treatment of synovial sarcoma (NCT04965753), and the CFT8634 degrader has recently entered phase I/II clinical trials for synovial sarcoma and SMARCB1-null solid tumors (NCT05355753). This evidence concerns the gene SMARCB1 and synovial sarcoma.